RESUMO
The use of antimicrobials as growth promoters and disease prevention is being constantly reduced in several animal production systems, including in the swine industry. Therefore, this study aimed to evaluate the effectiveness of using acidifiers to control Salmonella Typhimurium in 65-day-old pigs by detecting the pathogen in organs at euthanasia. For this, 24 piglets were divided into two experimental groups consisting of 12 piglets each. An untreated control group (G1) and a treatment group (G2) received a liquid organic acidifier in the drinking water for 10 days (D-5 to D5). Five days after the start of treatment (D0), all piglets were challenged with 106 CFU of Salmonella Typhimurium and assessed for 12 days (D12). Every three days (D3, D6, D9, and D12), three animals from each experimental group were euthanized and then submitted for necropsy. Samples from the intestines (ileum, cecum, mesenteric lymph nodes, and ileocolic lymph nodes), liver, spleen, and lungs were collected to isolate Salmonella. The results show that, numerically, Salmonellaisolation in the organs of G2 was lower than in G1 and that the number of positive cecum samples in G1 (66.7%; 8/12) was statistically different from the number of positive models in G2 (16.7%; 2/12), with a reduction of 28.6% of the total cecum positive samples in the treated group compared to the control. Therefore, it was observed that the liquid organic acidifier product could reduce the colonization of organs by Salmonella Typhimurium.(AU)
O uso de antimicrobianos como promotores de crescimento e prevenção de doenças vem sendo constantemente reduzido em diversos sistemas de produção animal, inclusive na suinocultura. Portanto, o objetivo do presente estudo foi avaliar a eficácia do uso de acidificantes no controle de Salmonella Typhimurium em suínos de 65 dias de idade, detectando o patógeno em órgãos após a eutanásia. Para isso, 24 leitões foram divididos em dois grupos experimentais constituídos por 12 leitões cada. Um grupo controle não tratado (G1) e um grupo de tratamento (G2) que recebeu um acidificante orgânico líquido na água de beber por 10 dias (D-5 a D5). Cinco dias após o início do tratamento (D0), todos os animais foram inoculados oralmente com 106 UFC de Salmonella Typhimurium e avaliados por 12 dias (D12). A cada três dias (D3, D6, D9 e D12), três leitões de cada grupo experimental foram eutanasiados e posteriormente submetidos à necropsia. Amostras de intestino (íleo, ceco, linfonodos mesentéricos e linfonodos ileocólicos), fígado, baço e pulmões foram coletadas para o isolamento de Salmonella. Os resultados mostram que, numericamente, o isolamento de Salmonella nos órgãos do G2 foi inferior ao G1, e que o número de amostras positivas de ceco no G1 (66,7%; 8/12) foi estatisticamente diferente do número de amostras positivas no G2 (16,7%; 2/12), com redução de 28,6% do total de amostras positivas de ceco no grupo tratado em relação ao controle. Portanto, observou-se que o ácido orgânico líquido foi capaz de reduzir a colonização de órgãos por Salmonella Typhimurium.(AU)
Assuntos
Animais , Salmonella typhimurium/efeitos dos fármacos , Suínos/fisiologia , Ácidos Orgânicos/efeitos adversos , Salmonelose Animal/tratamento farmacológico , Eliminação de Partículas ViraisRESUMO
The present work recorded the impact of using Mycoplasma gallisepticum vaccines on post-vaccinal response and protection against challenge with Newcastle disease virus. Specific pathogen-free chickens were divided into eight groups of forty chickens each. Group G1 was vaccinated with Mycoplasma gallisepticum live attenuated and Mycoplasma gallisepticum inactivated vaccines. Group G2 was vaccinated with Mycoplasma gallisepticum live attenuated, Mycoplasma gallisepticum inactivated and Newcastle disease inactivated vaccines. Group G3 was vaccinated with Mycoplasma gallisepticum live attenuated vaccine. Group G4 was vaccinated with Mycoplasma gallisepticum live attenuated and Newcastle disease inactivated vaccines. Group G5 was vaccinated with Mycoplasma gallisepticum inactivated vaccine. Group G6 was vaccinated with Mycoplasma gallisepticum inactivated and Newcastle disease inactivated vaccines. Group G7 was vaccinated with Newcastle disease inactivated vaccine. Group G8 was kept as non-vaccinated control. The Newcastle disease hemagglutination inhibition antibodies and mortality percentages were measured. Group G7 recorded the best protective Newcastle disease hemagglutination inhibition antibody titer (7 log2). Group G2 recorded a marginal satisfactory antibody titer (6 log2) after vaccination by the three tested vaccines. The remaining groups revealed unsatisfactory titers ranged from 0-5. The protection levels for G2, G4, G6 and G7 ranged from 70percent to 100percent, but only G2 and G7 were considered protected. G1, G3, G5 and G8 showed typical clinical signs of Newcastle disease. The Mycoplasma gallisepticum vaccines couldn't improve the response to Newcastle disease inactivated vaccine. The results suggest that Mycoplasma gallisepticum vaccination is immunosuppressive rather than immunomodulatory in Newcastle disease vaccination(AU)
En el presente trabajo se registró el impacto de la utilización de vacunas contra Mycoplasma gallisepticum sobre la respuesta posvacunal y la protección frente al reto con el virus de la enfermedad de Newcastle. Pollos libres de patógenos específicos se distribuyeron en ocho grupos de cuarenta pollos cada uno. El grupo G1 se vacunó con vacunas vivas atenuadas e inactivadas contra Mycoplasma gallisepticum. Al grupo G2 se le aplicaron las vacunas: viva atenuada contra Mycoplasma gallisepticum, inactivada contra Mycoplasma gallisepticum e inactivada contra la enfermedad de Newcastle. El grupo G3 se inmunizó con la vacuna viva atenuada contra Mycoplasma gallisepticum; el G4, con las vivas atenuadas contra Mycoplasma gallisepticum e inactivada contra la enfermedad de Newcastle; el G5, con la vacuna inactivada contra Mycoplasma gallisepticum; el G6 con las vacunas inactivadas contra Mycoplasma gallisepticum y la enfermedad de Newcastle; el G7, con la vacuna inactivada contra la enfermedad de Newcastle y el G8 se mantuvo como control no vacunado. Se midieron los anticuerpos de inhibición de la hemaglutinación contra el virus de la enfermedad de Newcastle y los porcentajes de mortalidad. El grupo G7 registró el mejor título de anticuerpos inhibidores de la hemaglutinación contra la enfermedad de Newcastle (7 log2). El grupo G2 registró un título de anticuerpos marginalmente satisfactorio (6 log2) tras la vacunación con las tres vacunas ensayadas. Los demás grupos revelaron títulos insatisfactorios que oscilaban entre 0 y 5. Los niveles de protección de los grupos G2, G4, G6 y G7 oscilaron entre el 70 por ciento y el 100 por ciento, pero sólo G2 y G7 se consideraron protegidos. Los grupos G1, G3, G5 y G8 mostraron signos clínicos típicos de la enfermedad de Newcastle. Las vacunas contra Mycoplasma gallisepticum no pudieron mejorar la respuesta a la vacuna inactivada contra la enfermedad de Newcastle. Los resultados revelan que la vacunación con Mycoplasma gallisepticum es más inmunosupresora que inmunomoduladora en la vacunación contra la enfermedad de Newcastle(AU)
Assuntos
Animais , Doenças das Aves Domésticas , Galinhas , Eliminação de Partículas Virais , Conservação de Alimentos/métodos , Infecções por Mycoplasma/mortalidade , Doença de Newcastle/mortalidade , EgitoRESUMO
Con el propósito de ampliar el conocimiento epidemiológico sobre la circulación del SARS-CoV-2 en la ciudad de Ushuaia durante el brote ocurrido de marzo a mayo de 2020, nos planteamos realizar un estudio observacional, de corte transversal, de mayo a julio, buscando la respuesta serológica al contacto con el virus en trabajadores esenciales municipales. N=1305. Los datos fueron ingresados a una plataforma con ingreso restringido, para luego cruzar las variables obtenidas en formato Excel. La mayoría de las personas estudiadas fueron de género masculino, con una media de edad de 38,5 años. El 20% de las personas con IgG+ tuvieron nexo epidemiológico. La prevalencia fue del 2,75%. Quienes presentaron IgM+ fueron descartados por otro método, considerándose falsos positivos. La idea y realización en forma precoz del estudio fue útil para evaluar la diseminación viral asintomática en el personal municipal afectado a tareas esenciales y tomar decisiones en las primeras etapas de la pandemia. No se encontraron diferencias significativas en los grupos más expuestos. Se observaron casos de transmisión asintomática intrafamiliar. Estas pruebas serológicas no tienen fines diagnósticos ni confieren un pasaporte inmunitario. Pudimos establecer la confiabilidad de la técnica utilizada, fundamentalmente en relación a la IgG. El método se optimizó. Consideramos que las políticas públicas basadas en evidencias científicas permiten tomar mejores decisiones en beneficio de la comunidad. Creemos que el presente estudio aporta al estado de comprensión en la materia. Cada reporte puede ser de utilidad para el conocimiento de la diseminación viral
With the purpose of expanding epidemiological knowledge about the circulation of SARS-CoV-2 in the city of Ushuaia during the outbreak that occurred from March to May of this current, we plan to carry out an observational, cross-sectional study from May to July, seeking the serological response to contact with the virus in essential municipal workers. N = 1316. The data were entered into a platform with restricted entry, to later cross the variables obtained in Excel format. Most of the people studied were male, with a mean age of 38 years. 20% of the people with IgG + had an epidemiological link. The prevalence was 2.88%. Those who presented IgM+ were discarded by another method, being considered false positives. The early idea and implementation of the study was useful to evaluate asymptomatic viral shedding in municipal personnel affected by essential tasks and to make decisions in the early stages of the pandemic. No significant differences were found in the most exposed groups. Cases of asymptomatic interfamily transmission were observed. These serological tests do not have diagnostic purposes nor do they confer an immune passport. We were able to establish the reliability of the technique used, mainly in relation to IgG. The method was optimized. We believe that public policies based on scientific evidence allow us to make better decisions for the benefit of the community. We believe that the present study contributes to the state of understanding in the matter. Each report can be useful for understanding viral shedding.
Assuntos
Humanos , Adulto , Imunoglobulina G/imunologia , Imunoglobulina M/imunologia , Estudos Transversais , Pessoal de Saúde , Eliminação de Partículas Virais/imunologia , Administração Municipal , Teste Sorológico para COVID-19 , COVID-19/epidemiologiaRESUMO
BACKGROUND@#We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62 hospitals and three non-hospital recuperation facilities.@*METHODS@#Logistic regression analysis was performed to investigate the factors associated with prolonged (29 days: upper 25% in duration) viral clearance of SARS-CoV-2. Linear regression analysis was conducted to assess these factors 14 days after symptom onset.@*RESULTS@#The median duration of viral clearance was 22 days from symptom onset. After adjustment for sex, age, symptoms, comorbidity, and location of recuperation, comorbidities were associated with prolonged duration: (OR, 1.77 [95% CI, 1.11-2.82]) for one, (OR, 2.47 [95% CI, 1.32-4.61]) for two or more comorbidities. Viral clearance 14 days after symptom onset was 3 days longer for one comorbidity and 4 days longer for two or more comorbidities compared to clearance when there was no comorbidity.@*CONCLUSION@#The presence of comorbidity was a robust factor associated with a longer duration of viral clearance, extending by 3 to 4 days compared to patients with no comorbidity.
Assuntos
Adulto , Humanos , COVID-19 , Japão/epidemiologia , RNA Viral , SARS-CoV-2 , Eliminação de Partículas ViraisRESUMO
With the number of cases of coronavirus disease-2019 (COVID-19) increasing rapidly, the World Health Organization (WHO) has recommended that patients with mild or moderate symptoms could be released from quarantine without nucleic acid retesting, and self-isolate in the community. This may pose a potential virus transmission risk. We aimed to develop a nomogram to predict the duration of viral shedding for individual COVID-19 patients. This retrospective multicentric study enrolled 135 patients as a training cohort and 102 patients as a validation cohort. Significant factors associated with the duration of viral shedding were identified by multivariate Cox modeling in the training cohort and combined to develop a nomogram to predict the probability of viral shedding at 9, 13, 17, and 21 d after admission. The nomogram was validated in the validation cohort and evaluated by concordance index (C-index), area under the curve (AUC), and calibration curve. A higher absolute lymphocyte count (
Assuntos
Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Anticorpos Antivirais/sangue , Área Sob a Curva , COVID-19/virologia , Contagem de Linfócitos , Nomogramas , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Carga Viral , Eliminação de Partículas ViraisRESUMO
Abstract INTRODUCTION: Considering the persistent positivity on RT-qPCR tests, the results of SARS-CoV-2 were monitored to evaluate the viral RNA shedding period. METHODS: Between March and June 2020, the sequential results of 29 healthcare workers' were monitored using RT-qPCR. RESULTS: More than 50% of the individuals remained RT-qPCR positive after 14 days. Furthermore, this is the first study to describe positive RT-qPCR for SARS-CoV-2 in a healthcare worker with mild symptoms 95 days after the first positive test. CONCLUSIONS: Sequential RT-qPCR results were heterogeneous, and the viral RNA shedding period is unique for each person.
Assuntos
Humanos , Ácidos Nucleicos , COVID-19 , RNA Viral/genética , Eliminação de Partículas Virais , Reação em Cadeia da Polimerase em Tempo Real , SARS-CoV-2RESUMO
O objetivo deste trabalho foi evidenciar o papel dos viajantes na transmissão e na disseminação do novo coronavírus. A busca pelos artigos foi realizada nas bases de dados PubMed®, SciELO, MEDLINE®, Cochrane, Center for Disease Control and Prevention e UpToDate. Foram incluídos artigos relacionados à transmissibilidade, principalmente aqueles associados à disseminação realizada por viajantes, do novo coronavírus. Excluíram-se artigos relacionados a outros surtos de coronavírus. Todos os estudos foram lidos e analisados integralmente. Onze artigos foram selecionados e tabulados, dos quais se pôde desenvolver uma fundamentação teórica, que expõe o grande impacto dos viajantes perante o crescimento da pandemia relacionada ao SARS-CoV-2, levando em consideração as diversas formas com que esse vírus pode se propagar, sendo elas por contato com superfícies contaminadas ou pessoa a pessoa, visto que a infecção pode ser decorrente de gotículas, aerossóis, fômites e, possivelmente, contato sexual, estando os indivíduos sintomáticos ou não.
The objective of this study was to highlight the travelers role in the transmission and dissemination of new coronavirus. The search for the articles was carried out in PubMed®, SciELO, MEDLINE®, Cochrane, Centers for Disease Control and Prevention, and UpToDate databases. Articles related with transmissibility of the new coronavirus were included, mainly those linked with the dissemination from travelers. Articles related with other coronavirus outbreaks were excluded. All of the studies were read and analyzed in their entirety. Eleven articles were selected and tabulated, from which a theoretical framework was developed, which exposes the great impact of travelers in the face of the growth of the pandemic related to the SARS-CoV-2, considering the several ways in which this virus can spread, either through contact with contaminated surfaces or person-to-person, since the infection may occur through droplets, aerosols, fomites, and possibly sexual contact, whether individuals are symptomatic or not.
Assuntos
Humanos , Masculino , Feminino , Portador Sadio , Eliminação de Partículas Virais , Controle Sanitário de Viajantes , SARS-CoV-2/patogenicidade , COVID-19/transmissão , Doenças Transmissíveis Importadas/diagnóstico , Teste para COVID-19 , SARS-CoV-2/isolamento & purificação , COVID-19/diagnósticoRESUMO
BACKGROUND@#Currently, there are no drugs that have been proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because of its broad antiviral activity, interferon (IFN) should be evaluated as a potential therapeutic agent for treatment of coronavirus disease 2019 (COVID-19), especially while COVID-19-specific therapies are still under development.@*METHODS@#Confirmed COVID-19 patients hospitalized in the First Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China, from January 19 to February 19, 2020 were enrolled in a retrospective study. The patients were separated into an IFN group and a control group according to whether they received initial IFN-α2b inhalation treatment after admission. Propensity-score matching was used to balance the confounding factors.@*RESULTS@#A total of 104 confirmed COVID-19 patients, 68 in the IFN group and 36 in the control group, were enrolled. Less hypertension (27.9% vs. 55.6%, P=0.006), dyspnea (8.8% vs. 25.0%, P=0.025), or diarrhea (4.4% vs. 19.4%, P=0.030) was observed in the IFN group. Lower levels of albumin and C-reactive protein and higher level of sodium were observed in the IFN group. Glucocorticoid dosage was lower in the IFN group (median, 40 vs. 80 mg/d, P=0.025). Compared to the control group, fewer patients in the IFN group were ventilated (13.2% vs. 33.3%, P=0.015) and admitted to intensive care unit (ICU) (16.2% vs. 44.4%, P=0.002). There were also fewer critical patients in the IFN group (7.4% vs. 25.0%, P=0.017) upon admission. Although complications during admission process were comparable between groups, the discharge rate (85.3% vs. 66.7%, P=0.027) was higher and the hospitalization time (16 vs. 21 d, P=0.015) was shorter in the IFN group. When other confounding factors were not considered, virus shedding time (10 vs. 13 d, P=0.014) was also shorter in the IFN group. However, when the influence of other factors was eliminated using propensity score matching, virus shedding time was not significantly shorter than that of the control group (12 vs. 15 d, P=0.206).@*CONCLUSIONS@#IFN-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients.
Assuntos
Humanos , Albuminas/análise , Antivirais/administração & dosagem , Betacoronavirus , Proteína C-Reativa/análise , COVID-19 , Estudos de Casos e Controles , China , Infecções por Coronavirus/tratamento farmacológico , Glucocorticoides/farmacologia , Hospitalização , Interferon alfa-2/administração & dosagem , Sprays Nasais , Pandemias , Pneumonia Viral/tratamento farmacológico , Pontuação de Propensão , Estudos Retrospectivos , SARS-CoV-2 , Sódio/sangue , Eliminação de Partículas Virais/efeitos dos fármacos , Tratamento Farmacológico da COVID-19RESUMO
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was found initially in Wuhan, China in early December 2019. The pandemic has spread to 216 countries and regions, infecting more than 23310 000 people and causing over 800 000 deaths globally by Aug. 24, 2020, according to World Health Organization (https://www.who.int/emergencies/diseases/ novel-coronavirus-2019). Fever, cough, and dyspnea are the three common symptoms of the condition, whereas the conventional transmission route for SARS-CoV-2 is through droplets entering the respiratory tract. To date, infection control measures for COVID-19 have been focusing on the involvement of the respiratory system. However, ignoring potential faecal transmission and the gastrointestinal involvement of SARS-CoV-2 may result in mistakes in attempts to control the pandemic.
Assuntos
Humanos , Betacoronavirus/isolamento & purificação , COVID-19 , China/epidemiologia , Infecções por Coronavirus/virologia , Microbiologia Ambiental , Fezes/virologia , Gastroenteropatias/virologia , Modelos Biológicos , Pandemias , Pneumonia Viral/virologia , RNA Viral/genética , SARS-CoV-2 , Eliminação de Partículas ViraisRESUMO
Con el avance de la pandemia por COVID-19, la aparición de pacientes con un segundo episodio confirmado por reacción en cadena de la polimerasa, con transcripción inversa (rt-PCR) compatible con reinfección, puso de manifiesto la falta de recomendaciones para su abordaje.Presentamos un estudio descriptivo multicéntrico retro-prospectivo de una serie de doce casos atendidos entre el 01/06/2020 y el 20/10/2020. En la misma, diez casos presentaron el segundo episodio en un período de tiempo menor a 90 días.Por su complejidad, la confirmación de una reinfección no está al alcance en la práctica diaria. Esto requiere de estudios que incluyan comparaciones genómicas de cepas virales involucradas en ambos episodios, determinación de la infectividad del ARN por cultivo viral y análisis molecular.Es necesario establecer definiciones operativas y algoritmos clínicos para la atención de los segundos episodios
As COVID-19 pandemic progresses, patients with a second confirmed episode by reverse transcription-polymerase chain reaction (RT PCR) compatible with reinfection reveals the lack of recommendations for its approach.A multicenter retro-prospective descriptive work was done of a series of 12 cases evaluated between June 1, 2020 and October 20, 2020. In this study, 10 out of 12 cases presented the second episode occurred in less than 90 days.Due to the diagnosing reinfection complexity, its confirmation is not available in the daily practice, this requires studies, which include viral strains genomic comparisons involved in both episodes, ARN determination infectivity by viral culture and molecular analysis.It is necessary to establish operational and clinical algorithms definitions to assist second episodes
Assuntos
Humanos , Adulto , Pessoa de Meia-Idade , Idoso , Epidemiologia Descritiva , Estudos Retrospectivos , Estudo Multicêntrico , Eliminação de Partículas Virais , Tomada de Decisões , Assistência Ambulatorial , Reinfecção/terapia , RNA-Polimerase RNA-Dependente de Coronavírus/imunologia , HospitalizaçãoRESUMO
ABSTRACT SARS-CoV-2 is a novel virus which has proven to be highly contagious. Specific viral dynamics and immune response to the virus are yet to be fully defined and determining the sensitivity and specificity of the available testing methods is still a work in progress. This study examines the published information on the testing methods, and finds that yield of COVID-19 tests changes with specimen types and with time through course of illness. We propose a sequential battery of testing consisting of an epidemiologic survey, RT-PCR tests, serologic tests and chest CT on surgical candidates which may increase the negative predictive value, and facilitate surgical procedures.
RESUMO O SARS-CoV-2 é um novo vírus que provou ser altamente contagioso. A dinâmica viral específica e a resposta imunológica ao vírus ainda não foram totalmente definidas e a determinação da sensibilidade e especificidade dos métodos de teste disponíveis ainda está em andamento. Este estudo examina as informações publicadas sobre os métodos de testagem e conclui que o rendimento dos testes COVID-19 muda de acordo com o tipo de amostra e com o tempo de progressão da doença. Propomos uma bateria sequencial de testes, que consiste em um levantamento epidemiológico, testes de RT-PCR, testes sorológicos e tomografia computadorizada de tórax em candidatos a cirurgia, que podem aumentar o valor preditivo negativo e facilitar procedimentos cirúrgicos.
Assuntos
Humanos , Pneumonia Viral/diagnóstico , Procedimentos Cirúrgicos Eletivos , Infecções por Coronavirus/diagnóstico , Pneumonia Viral/imunologia , Valor Preditivo dos Testes , Eliminação de Partículas Virais , Infecções por Coronavirus/imunologia , Técnicas de Laboratório Clínico , Pandemias , Betacoronavirus , Teste para COVID-19 , SARS-CoV-2 , COVID-19 , Formação de AnticorposRESUMO
In 2016, novel H5N6 highly pathogenic avian influenza virus emerged in Korea. During the outbreak, the virus caused the largest culling, especially in brown chicken lines. We determined the pathogenicity and transmissibility of the virus in 2 white chicken lines of the specific pathogen-free chickens, broilers and brown chicken line of Korean native chicken (KNC). A KNC had a longer virus shedding period and longer mean death time than others. Our study showed that this characteristic in the KNC might have contributed to a farm-to-farm transmission of the brown chicken farms.
Assuntos
Animais , Agricultura , Galinhas , Influenza Aviária , Coreia (Geográfico) , Virulência , Eliminação de Partículas ViraisRESUMO
Foot-and-mouth disease (FMD) is an acute epidemic that spreads rapidly among cattle and pigs. In 2014, in Korea, despite enforced vaccination, the type O Southeast Asia (SEA) topotype viruses (Mya-98 lineage) infected mainly cattle and pigs simultaneously, thereby causing enormous damage. If a vaccine that is completely protective against this FMD virus is developed and used, it can become a very important preventive measure in Asia, which is where this type of virus mainly circulates. The SEA topotype has been steadily evolving and transforming into new variations since it became epidemic in Asia. Therefore, it became necessary to develop a new vaccine that could provide protection against the FMD virus strain that was responsible for the 2014–2015 outbreak in Korea. This study aimed to develop a vaccine that would provide complete protection against the SEA topotype FMD virus to control sporadic FMD outbreaks, which occur despite the enforcement of vaccination, and to completely prevent virus shedding, thereby preventing the virus from spreading. The vaccine candidate virus developed in this study showed low pathogenicity and can be distinguished from the wild-type FMD virus strain. The developed vaccine was able to protect mice from SEA and Middle East–South Asia topotype virus strains and induced high titers of antibodies against both virus strains in pigs, thereby confirming the sufficiency of its protective function. In particular, the results of the SEA topotype virus challenge test in pigs revealed that perfect immunity was created in the vaccinated pigs, without virus shedding and viremia.
Assuntos
Animais , Bovinos , Camundongos , Anticorpos , Ásia , Sudeste Asiático , Surtos de Doenças , Febre Aftosa , Coreia (Geográfico) , Suínos , Vacinação , Viremia , Virulência , Eliminação de Partículas ViraisRESUMO
To prevent the spread of influenza among infants and adolescents attending kindergartens and schools, proper quarantining of those who are ill is necessary. In this study, the rapid antigen test (RAT) was performed in patients to investigate the factors affecting the duration of virus shedding. The study included pediatric patients who were diagnosed with influenza by RAT at Daedong Hospital between November 2016 and April 2019. We identified the influenza subtype, age, gender, fever duration, oseltamivir medications, and time gap between fever subsided and RAT examination through chart review. A total of 330 patients were examined at discharge. The average age for RAT positive and negative patients was 6.32 ± 4.26 years and 8.47 ± 4.54 years, respectively. The average duration of fever for the RAT positive patients was 3.84 ± 1.09 days, and for those who were RAT negative was 4.191 ± 1.39. The average number of doses oseltamivir for RAT positive and negative patients was 7.68 ± 1.57 and 8.72 ± 1.37, respectively. The RAT was performed 24 to 48 hours after fever subsided (TG 24–48H group). At this time, 60 patients were positive and the rate of positive expression was 55.56%. Of the TG 48–72H group, 36 patients (26.09%) were positive. Of the TG 72–96H group, 18 patients (21.43%) were positive. Age, fever duration, number of doses oseltamivir and time gap after fever subsided were the factors that influenced the duration of influenza virus shedding. These factors should be considered during the quarantining influenza patients.
Assuntos
Adolescente , Animais , Criança , Humanos , Lactente , Ratos , Febre , Influenza Humana , Orthomyxoviridae , Oseltamivir , Pediatria , Eliminação de Partículas ViraisRESUMO
Abstract Objectives: This study aimed to verify the presence of polyomavirus BK (BKPyV) in the saliva of kidney transplant recipients and to correlate it with blood viremia. Material and Methods: We have conducted a cross-sectional study with a sample involving 126 renal transplant recipients. 126 samples of saliva and 52 samples of blood were collected from these patients. Detection and quantification of BKPyV were performed using a real-time PCR. To compare the presence of BKPyV in blood and saliva, the binomial proportion test was used. To verify associations between salivary shedding BKPyV and post-transplant periods (in months), the Mann-Whitney test was used. Spearman's correlation was used to correlate the viral load in the saliva with blood of kidney transplant recipients. Results: The mean age of the study group was 51.11±12.45 years old, and 69 participants (54.8%) were female, with a mean post-transplantation time of 4.80±6.04 months. BKPyV was quantified in several samples of saliva and blood, with medians of 1,108 cp/mL and 1,255 cp/mL, respectively. Only 16/52 (30.8%) participants presented BKPyV in blood, and 59/126 (46.8%) excreted the virus in saliva (p=0.004). BKPyV shedding was found in patients at a shorter post-transplantation period (3.86±5.25, p=0.100). A weak correlation was observed between viral quantification in saliva and blood (Spearman's correlation coefficient=0.193). Conclusion: The results of this study suggested that, although saliva excretes more BKPyV than blood, there is no reliable correlation between salivary shedding and blood viremia, showing two independent compartments of viral replication.
Assuntos
Humanos , Masculino , Feminino , Adulto , Saliva/virologia , Viremia , Transplante de Rim/efeitos adversos , Eliminação de Partículas Virais , Vírus BK/isolamento & purificação , Transplantados , Infecções Tumorais por Vírus/virologia , Estudos Transversais , Terapia de Imunossupressão/efeitos adversos , Estatísticas não Paramétricas , Carga Viral , Infecções por Polyomavirus/virologia , Reação em Cadeia da Polimerase em Tempo Real , Imunocompetência , Pessoa de Meia-IdadeRESUMO
PURPOSE: The first aim of this study was to develop a novel inactivated porcine epidemic diarrhea virus (PEDV) vaccine using the recently isolated Korean PEDV QIAP1401 strain and to evaluate its protective efficacy in growing pigs. The second was to determine the optimum adjuvant formulation of the inactivated PEDV vaccine that induces protection against viral challenge. MATERIALS AND METHODS: To generate high titers of infectious PEDV, the QIAP1401 isolate was passaged in Vero cells. The experimental vaccines were prepared from a binary ethyleneimine-inactivated QIAP1401 strain passaged sequentially 70 times (QIAP1401-p70), formulated with four commercial adjuvants, and administered twice intramuscularly to growing pigs. Challenge studies using a virulent homologous strain of PEDV QIAP1401-p11, which was passaged 11 times after isolation, were performed to assess protection against disease progression and viral shedding during the 15-day observation period. The vaccine-induced antibody responses were measured in serum samples collected at predetermined time points by indirect enzyme-linked immunosorbent assay and virus neutralization test. RESULTS: The QIAP1401-p70 strain had 42 amino acid (aa) mutations, including a 25 aa deletion, and was selected as the inactivated PEDV vaccine candidate. Although none of the pigs that received the experimental vaccines were completely protected against subsequent viral challenge, they exhibited a significantly higher immune response than did non-vaccinated control pigs. Among the vaccine groups, the highest antibody responses were observed in the pigs that received an oil-based multiphasic water/oil/water (W/O/W) emulsion adjuvanted vaccine, which delayed the onset of clinical symptoms and viral shedding. CONCLUSION: A novel inactivated PEDV vaccine formulated with a W/O/W emulsion adjuvant was both immunogenic and protective against viral challenge.
Assuntos
Formação de Anticorpos , Progressão da Doença , Ensaio de Imunoadsorção Enzimática , Testes de Neutralização , Vírus da Diarreia Epidêmica Suína , Suínos , Vacinas , Células Vero , Eliminação de Partículas ViraisRESUMO
Zika is a re-emerging, mosquito-borne viral infection, which has been recently shown to cause microcephaly and Guillain-Barré syndrome. Since 2015 the number of infected patients has increased significantly in South America. The purpose of this study was to identify the epidemiologic and clinical characteristics of patients with Zika virus (ZIKV) infections in Korea. Patients who had visited areas of risk and tested positive in the ZIKV reverse transcriptase polymerase chain reaction (RT-PCR) in blood, urine, or saliva specimens were included. The first Korean case of ZIKV infection was reported in March 2016, and 14 cases had been reported by October 2016. The median age of the patients was 34 years (19–64 years). Ten patients had been exposed in Southeast Asia and 4 in Latin America. Rash was the most common symptom (92.9%; 13/14), followed by myalgia (50.0%; 7/14), and arthralgia (28.6%, 4/14). There were no neurologic abnormalities and none of the patients was pregnant. Results of biochemical tests were normal. Positivity rates of RT-PCR for ZIKV in serum, urine, and saliva were 53.8%, 100.0%, and 83.3%, respectively in the first week of symptoms. In conclusion, 14 patients with ZIKV infections were reported in Korea by October 2016 and all of them had mild clinical symptoms.
Assuntos
Humanos , Artralgia , Sudeste Asiático , Epidemiologia , Exantema , Síndrome de Guillain-Barré , Coreia (Geográfico) , América Latina , Microcefalia , Mialgia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Saliva , América do Sul , Eliminação de Partículas Virais , Zika virusRESUMO
Abstract This study was designed with the goal of adding as much information as possible about the role of pigeons (Columba livia) and chickens (Gallus gallus) in Newcastle disease virus epidemiology. These species were submitted to direct experimental infection with Newcastle disease virus to evaluate interspecies transmission and virus-host relationships. The results obtained in four experimental models were analyzed by hemagglutination inhibition and reverse transcriptase polymerase chain reaction for detection of virus shedding. These techniques revealed that both avian species, when previously immunized with a low pathogenic Newcastle disease virus strain (LaSota), developed high antibody titers that significantly reduced virus shedding after infection with a highly pathogenic Newcastle disease virus strain (São Joao do Meriti) and that, in chickens, prevent clinical signs. Infected pigeons shed the pathogenic strain, which was not detected in sentinel chickens or control birds. When the presence of Newcastle disease virus was analyzed in tissue samples by RT-PCR, in both species, the virus was most frequently found in the spleen. The vaccination regimen can prevent clinical disease in chickens and reduce viral shedding by chickens or pigeons. Biosecurity measures associated with vaccination programs are crucial to maintain a virulent Newcastle disease virus-free status in industrial poultry in Brazil.
Assuntos
Animais , Doença de Newcastle/patologia , Doença de Newcastle/virologia , Vírus da Doença de Newcastle/crescimento & desenvolvimento , Estruturas Animais/virologia , Anticorpos Antivirais/sangue , Brasil , Galinhas , Columbidae , Modelos Animais de Doenças , Transmissão de Doença Infecciosa , Testes de Inibição da Hemaglutinação , Interações Hospedeiro-Patógeno , Doença de Newcastle/imunologia , Doença de Newcastle/transmissão , Vírus da Doença de Newcastle/imunologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Eliminação de Partículas ViraisRESUMO
<p><b>OBJECTIVE</b>To investigate the features and duration of viral nucleic acid shedding in children with influenza A.</p><p><b>METHODS</b>The clinical data of 90 children with influenza A with positive influenza A virus nucleic acid in nasopharyngeal swab detected by PCR were collected, and these children were divided into simple influenza A group (n=10), influenza A-pneumonia group (n=61), influenza A-nervous system damage group (n=10), and influenza A-underlying disease group (n=9). A retrospective analysis was performed for clinical features, treatment process, duration of viral nucleic acid shedding, and prognosis.</p><p><b>RESULTS</b>The most common symptoms in these children were fever (89/90, 99%), cough (89/90, 99%), running nose (69/90, 77%), shortness of breath (26/90, 29%), and myalgia (23/90, 26%). The mean duration of viral nucleic acid shedding in 90 children was 9.4±2.9 days. The simple influenza A group had a significantly shorter duration of viral nucleic acid shedding than the influenza A-pneumonia, influenza A-nervous system damage, and influenza A-underlying disease groups (p<0.05), while there were no significant differences between the influenza A-pneumonia, influenza A-nervous system damage, and influenza A-underlying disease groups (p>0.05). The children who received antiviral therapy within 48 hours after disease onset had significantly shorter duration of viral nucleic acid shedding and time to body temperature recovery than those who received antiviral therapy more than 48 hours after disease onset (p<0.05). Of all the children with body temperature recovery, 83% still tested positive for viral nucleic acid.</p><p><b>CONCLUSIONS</b>Complications, underlying diseases, and timing of antiviral therapy are influencing factors for the duration of influenza A virus nucleic acid shedding, and whether body temperature returns to normal cannot be used to decide whether to continue antiviral therapy.</p>